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Perspective
Introduction
Relatively recent developments in our understanding of 
sarcomeric proteins have expanded their role from the 
home of molecular motors generating force and shorten-
ing to a cellular organelle fully integrated in the control of 
structural, electrical, mechanical, chemical, and metabolic 
homeostasis. Even so, in some cases these diverse func-
tions of sarcomeric proteins appear to remain a curiosity, 
not fully appreciated in the analysis of major controllers of 
cardiac function. This attitude toward the function of sar-
comeric proteins in cardiac myocytes is summarized in the 
following definition of “curiosity,” which seems particu-
larly apropos: “meddlesome; thrusting oneself into and 
taking an active part in others’ affairs.” We focus in this 
Perspective on how sarcomeric proteins function in inte-
gration with membrane channels and transporters in con-
trol of cardiac dynamics, especially in adrenergic control 
of cardiac function. Understanding these mechanisms at 
the level of cardiac sarcomeres took on special significance 
with the identification of mutations in sarcomeric proteins 
as the most common cause of familial hypertrophic and 
dilated  cardiomyopathies.  These  mutations  commonly 
lead to structural, electrical, and metabolic remodeling 
and to sudden death. These disorders indicate a critical 
role of processes at the level of the sarcomeres in homeo-
static control of cardiac energetics, dynamics, and struc-
ture. Yet, control of Ca
2+ delivery to and removal from the 
myofilaments has dominated discussions of mechanisms 
regulating cardiac contractility. We first provide an alterna-
tive perspective in which rate processes at the level of the 
sarcomeres appear to be dominant during the rise and 
maintenance of systolic elastance and of isovolumic relax-
ation. A discussion of established adrenergic mechanisms 
and newly understood anti-adrenergic mechanisms con-
Correspondence to R. John Solaro: solarorj@ﾭuic.edu
Abbreviations used in this paper: Ip, inhibitory peptide; MLC2, myo-
sin light chain 2; MyBP-C, myosin-binding protein C; Pak, p21-activated   
kinase; PP2A, protein phosphatase 2A; Tm, tropomyosin; TnC, troponin 
C; TnI, troponin I; TnT, troponin T.
trolling sarcomere response to Ca
2+ follows and expands 
on this perspective.
Are kinetic processes intrinsic to the cardiac  
sarcomeres rate limiting in the contraction–relaxation  
cycle of the heart?
During the cardiac cycle, there is universal agreement 
that Ca
2+ released from stores in the myocytes binds to 
troponin C (TnC) and sets into motion a set of protein– 
protein interactions, which promote an ATP-dependent 
reaction of cross-bridges with actin, inducing force 
(pressure) and shortening (ejection). Reversal of these 
protein–protein interactions occurs with Ca
2+ removal 
from the sarcoplasm. Fig. 1 illustrates protein–protein 
interactions  among  sarcomeric  proteins  in  thin  fila-
ment functional regulatory units: seven actins in 1:1:1:1 
complex with tropomyosin (Tm), TnC, troponin I (TnI), 
and troponin T (TnT). The thin filament unit on the 
left is relaxed, and the one on the right has been acti-
vated by Ca
2+ binding to TnC. Fig. 1, which also shows a 
depiction of the thick filament with cross-bridges and a 
portion of titin, emphasizes the rich array of potential 
protein–protein interactions for control of force and 
shortening downstream of Ca
2+ binding to TnC. The or-
igins of the cartoon in Fig. 1 have been reviewed else-
where (Kobayashi and Solaro, 2005) and include recent 
structural information (Galińska-Rakoczy et al., 2008). 
In diastolic levels of cellular Ca
2+, the thin filament reg-
ulatory units remain relaxed via the actions of compo-
nents  of  Tn,  which  immobilize  Tm  and  depress  the 
reactivity of actin with myosin. Fig. 1 illustrates a new 
concept of the protein interactions, which wedge and 
immobilize Tm with actin-binding peptides of TnI bind-
ing on one side of Tm and the N-terminal extension of 
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peptide of TnI, which contains two prominent phos-
phorylation sites at S23 and S24 that are substrates for 
PKA, PKG, PKD, and PKC- (Solaro, 2008). When S23 
and S24 are not phosphorylated, the N-terminal pep-
tide binds to the N lobe of TnC and Ca
2+ affinity is rela-
tively high. With phosphorylation of S23 and S24, the 
peptide is released from TnC and there is drop in Ca
2+ 
affinity due to an enhanced off rate for Ca
2+ exchange. 
Thus, the sensitivity of force generation to Ca
2+ is lower 
when these TnI sites are phosphorylated. There is also 
evidence (Biesiadecki et al., 2007), albeit controversial 
(Sadayappan et al., 2005), that the phosphorylation of 
S23 and S24 also increases turnover kinetics of the   
actin–cross-bridge reaction. Fig. 1 also emphasizes the 
modulation of myofilament response to Ca
2+ by thick 
filament–related  mechanisms.  These  mechanisms   
involve myosin light chain 2 (MLC2), myosin-binding 
protein C (MyBP-C), and titin. All three of these pro-
teins control the propensity of interaction of the cross-
bridges with actin by altering the relative position of the 
cross-bridges with respect to the thick filament proper. 
MLC2 and MyBP-C restrict radial movements of cross-
bridges and thus control their local concentration in 
the vicinity of the actins (Colson et al., 2010). Phosphory-
lation controls this action of MLC2 and MyBP-C. Fig. 1 
shows only a small portion of the giant protein titin, 
which extends from the Z disk to the M line. Titin is 
largely responsible for the passive tension of cardiac   
myocytes and interacts with MyBP-C. Strong evidence 
TnT arising from a Tn on the adjacent actin strand 
binding to Tm on the other side. Cardiac TnI (cTnI) 
interacts with actin via two regions, a highly basic inhibi-
tory peptide (Ip) and a second actin-binding region. 
These regions flank a switch peptide, which binds to 
cTnC when Ca
2+ binds to cTnC. The C lobe of TnC   
intersects  with  near  N-terminal  regions  of  TnI  with   
C-terminal regions of TnT. New evidence indicates that 
the C-terminal region or mobile domain of cTnI (cTnI-C 
in Fig. 1) binds to the thin filament strand of actins with 
the far C terminus lying across and directly interacting 
with Tm. This state of the thin filament either blocks 
cross-bridges from reacting with actin or holds weakly 
bound  cross-bridges  in  a  nonforce-generating  state. 
Both blocked and weakly bound cross-bridges may also 
coexist. Binding of Ca
2+ to a single regulatory site at the 
N lobe of TnC activates the thin filament regulatory 
unit. Key reactions in this activation are an altered inter-
action of TnT with Tm and the promotion of an interac-
tion of the TnI switch peptide with TnC, thereby releasing 
TnI actin-binding peptides from their inhibitory location. 
The mobile domain of TnI most likely no longer interacts 
with actin or Tm. Actin–cross-bridge reactions are pro-
moted as Tm becomes mobile and actin reactivity is en-
hanced. The cross-bridge lever arm rotates as indicated in 
Fig. 1, thereby promoting force and shortening.
Fig.  1  also  illustrates  regulatory  domains  and  pro-
teins that significantly affect the response of the myofil-
aments to Ca
2+. We emphasize here a unique N-terminal 
Figure  1.  A  section  of  cardiac 
thin  filaments  illustrating  the   
position of troponin components 
with Tm in the OFF state (left) 
and ON state (right). Thin fila-
ments  are  shown  containing 
TnI,  TnT,  and  TnC.  cTnC,  a 
dumbbell-shaped  protein  with   
an N lobe containing a single   
regulatory Ca-binding site (yellow 
spheres) and a C lobe contain-
ing slowly exchanged Ca
2+/Mg
2+ 
sites. In the OFF state, Tm is im-
mobile and held in place by TnI, 
which is shown tethered to actin 
on an actin strand by an Ip and 
a  second  actin-binding  region 
flanking a switch peptide (Sw), 
which interacts with cTnC upon 
Ca activation. Note that the Ip of 
cTnI binds to one actin strand, 
whereas  the  N-terminal  tail  of 
TnT  interacts  with  Tm  on  the 
adjacent actin strand. The distal 
C-terminal  end  of  cTnI  drapes 
across azimuthal actins and may interact with Tm. TnI has a unique stretch of N-terminal amino acids, which contain phosphorylation 
sites at S23 and S24. The N peptide interacts with the N lobe of cTnC, but it is released upon phosphorylation. With release of Ca
2+, 
there is a release of cTnI from actin and binding of the switch peptide to cTnC. Activation is associated with release of Tm from an im-
mobilized state by protein signaling to cTnT and possible release of Tm from an interaction with the C-terminal end of cTnI. See Are 
kinetic processes intrinsic to... for further description.  Solaro et al. 15
between activation of the myofilaments by Ca
2+ and the 
activation of tension. This prediction raises the ques-
tion as to the mechanism of maintenance of systolic 
elastance. In our judgment, an excellent candidate is an 
induction of cooperative activation of the myofilaments, 
which recruits cross-bridges into force-generating states 
in regulatory units that do not contain bound Ca
2+. The 
dynamics of this cooperative activation have been esti-
mated in rat hearts from measurements of the pressure 
change  induced  by  rapid,  specified  volume  changes 
during a beat. The data and the predictions indicated 
that the time course of activation by Ca
2+ was relatively 
brief and of low relative magnitude compared with 
the time course of cooperative activation, which more 
closely coincided with tension, and was the dominant 
mechanism late in systole. An issue not fully resolved is 
how this cooperative activation reverses fast enough so 
as to not impair relaxation. Campbell et al. (2008) have 
addressed this issue in their model of the dynamics of 
left ventricular elastance, which incorporates a decay of 
the cooperative activation via what they term “elastic 
distortion dynamics.”
The role and mechanism of cooperative activation  
of the sarcomeres remains unclear
The  molecular  mechanism  of  cooperative  activation 
also remains controversial. Measurements of the steady-
state relation between force generation and Ca
2+ pro-
vide strong evidence for cooperativity in activation of 
the sarcomeres. Hill coefficients for this relation are 
generally 3–5 despite the presence of a single regula-
tory site on cTnC (Pan and Solaro, 1987). Two general 
theories are based on either a thick filament–dominated 
process with positive feedback of cycling, force-generat-
ing cross-bridges on activation (Moss et al., 2004), or a 
thin filament–based longitudinal spread of activation 
(Tobacman and Butters, 2000; Sun et al., 2009), which 
allosterically recruits blocked cross-bridges to a force 
generation reaction or recruits weakly bound cross-
bridges to a force-generating state. Data supporting a 
role for strongly bound cross-bridges in promotion of 
the active state of the thin filament are derived from 
studies using noncycling rigor cross-bridges or pseudo-
strong cross-bridges in the form of NEM-S1 (Moss et al., 
2004). Yet, when tested using cycling cross-bridges, a 
thick filament–based cooperative mechanism has not 
been  supported.  Moreover,  two  lines  of  experiments 
support  the  thin  filament–based  mechanism.  In  our 
studies (Davis et al., 2007), we measured Ca
2+ binding to 
the regulatory site of cTnC in reconstituted thin fila-
ments alone or reacting with myosin S-1 in the presence 
and absence of MgATP. There were similar cooperative 
Hill coefficients (nH = 1.65), Ca
2+-binding affinities, and 
off rates of Ca
2+ exchange with the cTnC regulatory site 
in both thin filaments alone and thin filaments plus   
S-1-MgATP. Ca
2+ affinity increased with a significant 
indicates that stretch of titin in diastole can affect sys-
tolic function by an interaction with MyBP-C, which 
promotes  the  radial  movement  of  cross-bridges  away 
from the thick filament.
Sarcomeric mechanisms controlling dynamics  
of the heart beat
With the advent of convenient to use fluorescent probes, 
many laboratories gained the ability to measure the tran-
sient change in Ca
2+ in isolated ventricular myocytes.   
Implicit in the interpretation of changes in the Ca
2+-tran-
sient amplitude and dynamics was that they define con-
tractility. Yet, in general, transient changes in Ca
2+ are 
out of phase with the dynamics of the mechanical events. 
For example, during increases in isometric tension, Ca
2+ 
rises faster than force and pressure (Kurihara and Allen, 
1982; Backx et al., 1995; Baran et al., 1997; Stull et al., 
2002). There is evidence that tension (pressure and sys-
tolic elastance) is maintained during the heart beat via 
processes at the level of the sarcomeric proteins. Relax-
ation also appears dominated by processes at the level of 
the sarcomeric proteins.
Studies of rate processes in the rise and maintenance 
of systole in the cardiac beat indicate an important rate 
limitation by the turnover kinetics of the force-generating 
reactions of the cross-bridges. During this rising phase 
of the heart beat, Ca
2+ is released into the myofilament 
space. There are no direct measurements of the relative 
in situ binding, but investigations of rates of Ca
2+ bind-
ing to cTnC in myofilament preparations with cycling 
cross-bridges indicate that the rate constant for bind-
ing is most likely diffusion limited and not rate limiting 
(Davis et al., 2007). The subsequent steps in the activa-
tion of thin filaments have been measured with the aid 
of fluorescent probes, and it is apparent that they may 
not be rate limiting as well (Stehle and Iorga, 2010). 
This indicates that the kinetic cycle of the cross-bridge 
reaction with actin is most likely the slow, rate-limiting 
process in the rise of ventricular pressure to the point of 
opening of the aortic valve. After the valve opens, ejection 
begins and systolic elastance is maintained. An impor-
tant and unresolved issue is the state of the myofilaments 
and the relative amounts of bound Ca
2+ during shorten-
ing. Again, we have no direct estimates of bound Ca
2+, 
but indirect evidence indicates that the fall in Ca
2+ 
bound to cTnC in an isometric twitch occurs well ahead 
of the drop in force. Peterson et al. (1991) estimated 
amounts of Ca
2+ bound from the rise in tension after 
quick detachment of cross-bridges. Bound Ca
2+ was esti-
mated  from  the  initial  rate  of  force  redevelopment. 
These  studies  demonstrated  that  when  the  isometric 
twitch force was near maximum, bound Ca
2+ had fallen 
to 50% of its peak, whereas when force had fallen to 
50% of its max, bound Ca
2+ was <10% of maximum. Pre-
vious  modeling  (Burkhoff,  1994;  Hinken  and  Solaro, 
2007)  had  also  predicted  this  temporal  difference   16 Integration of sarcomeric signaling
(Stehle et al., 2009). With a sudden drop in Ca
2+, sarco-
meres remain isometric for a time during which there is 
a relatively slow and relatively brief linear phase of re-
laxation of force, followed by a rapid fall in force associ-
ated  with  sequential  propagated  re-lengthening  of 
sarcomeres. The initial slow phase of relaxation involves 
the reversal of thin filament activation initiated by Ca
2+ 
release from cTnC, which is significantly slower than 
Ca
2+ binding to cTnC (Davis et al., 2007). Whether the 
fall  in  force  during  this  initial  period  of  relaxation   
is rate limited by Ca
2+ release from cTnC is not clear. 
Replacement of cTnI with slow skeletal TnI increases 
myofibrillar sensitivity to Ca
2+ and slows the off rate of 
Ca
2+ exchange with cTnC, but does not affect the relax-
ation kinetics of myofibrils held isometric. On the other 
hand, compared with wild-type hearts, ejecting hearts 
expressing slow skeletal TnI, a non-phosphorylatable 
isoform, demonstrate a significant impairment of re-
laxation  kinetics,  whereas  isovolumic  hearts  do  not 
(Layland et al., 2005). Similar findings have been re-
ported with hearts expressing cTnI pseudo-phosphor-
ylated  at  S23  and  S24  or  missing  the  N-terminal 
extension. Moreover, in studies with myofibrils, dele-
tion  of  Lys184  in  the  mobile  C-terminal  domain  of 
cTnI impaired the fast phase of relaxation (Iorga et al., 
2008). This mutation alters the ability of cTn to switch 
off  cross-bridge  cycling  but  not  turnover  kinetics. 
These data indicate a role for thin filament–related 
mechanisms and emphasize the complexity of the pro-
cesses at the level of the sarcomeres that determine re-
laxation kinetics.
With this perspective on the role of processes at the 
level of sarcomeres as major determinants of the dy-
namics of the cardiac cycle, it follows that we need to 
understand control mechanisms modifying these pro-
cesses in physiological states as well in inherited and   
acquired disorders of the heart. We next discuss physio-
logical control mechanisms with emphasis on a recently 
discovered anti-adrenergic pathway involving receptor 
signaling to protein phosphatase 2A (PP2A).
Yin and yang and adrenergic control of cellular Ca
2+ fluxes 
and sarcomere response to Ca
2+
The response of the heart to -adrenergic stimulation 
provides  an  excellent  example  of  how  sarcomere  re-
sponse to Ca
2+ and dynamics are coordinately controlled 
by the same signaling cascades that control Ca
2+ fluxes. 
In exercise, heart rate and contractility increase, but at 
the same time, the overall cycle time of the heart beat 
must be abbreviated so as not to impair filling time. The 
activation of -adrenergic signaling promotes phosphory-
lation of regulatory proteins (Ca
2+ channel subunits, 
phospholamban, and ryanodine receptors) of channels 
and transporters and promotes an increased release of 
Ca
2+ to the sarcomeres and increased uptake of Ca
2+ by 
the sarcoplasmic reticulum (for review see Bers, 2000). 
decrease in cooperativity (nH = 0.85), and the off rate 
slowed in the presence of rigor cross-bridges. Studies 
using fluorescent probes as sensors also demonstrated 
no effect of cycling cross-bridges of the on state of cTnC 
(Solaro, 2009b; Sun et al., 2009). These data indicate 
that the influence of strongly bound cross-bridges on 
thin filament activation may be most relevant during 
pathological states in which long-lived cross-bridge in-
teractions are present. The thin filament–based mech-
anism is appealing, but it requires more experimental 
proof. Ideally, it would be of great benefit to have an 
agent or a genetic approach specifically altering coop-
erative activation and applicable in the setting of the 
in situ beating heart.
Cross-bridge activity during systolic shortening  
and isovolumic relaxation
As outlined and discussed by Stehle and Iorga (2010), 
an unresolved issue is the question of what cross-bridges 
are doing during systolic shortening. Estimates of en-
ergy consumption indicate that the number of turnover 
cycles is about one per cross-bridge, yet the sarcomeres 
shorten by 10%. If sarcomere length is 2,000 nM, 
the thin filaments in a half-sarcomere move 100 nM. 
One cycle would be expected to move the thin filaments 
in a half-sarcomere by 8–10 nM. These considerations 
indicate that the cross-bridge may, in fact, act as thermal 
ratchet as proposed by Kitamura et al. (1999), repeat-
edly attaching and detaching from actin, but splitting 
only one ATP. In any case, the dwell time of the cross-
bridge force-generating interaction with the thin filament 
would be expected to be an important determinant of 
the duration of systolic elastance. Evidence supporting 
this idea comes from the effects of an inotropic agent 
(CK-1827452) under clinical development and demon-
strated to directly interact with myosin and to prolong 
the duration of the reaction of cross-bridges with actin 
and to prolong systole (Solaro, 2009a; Teerlink, 2009). 
Thick filament–associated proteins are also critical de-
terminants of systolic elastance. Palmer et al. (2004) re-
ported  an  abbreviation  of  the  time  course  and  peak 
amplitude of systolic elastance of hearts with myofila-
ments missing MyBP-C. Moreover, Scruggs et al. (2009) 
reported an abbreviation of the duration of systolic elas-
tance  in  hearts  expressing  a  non-phosphorylatable   
mutant, MLC2. These modifications appear to alter the 
radial movements of the myosin heads from the thick 
filament backbone, thereby altering the local concentra-
tions of cross-bridges in the vicinity of the thin filaments 
(Colson et al., 2010).
With the end of systole, isovolumic relaxation begins, 
and there is strong evidence that this phase of the car-
diac cycle is also dominated by processes at the level of 
the sarcomeres. Insights into what sarcomeres do dur-
ing isovolumic relaxation have been substantially influ-
enced by studies at the myofibrillar level of organization   Solaro et al. 17
sarcomeric Ca
2+ sensitivity is promoted, but active uptake 
by  the  sarcoplasmic  reticulum  is  not  altered  by  PLN. 
There is evidence that the predominant control of PLN 
dephosphorylation is via protein phosphatase 1. An im-
portant aspect of the Pak1-related control mechanism is 
that it also opposes the effects of -adrenergic stimula-
tion on heart rate at the sino-atrial nodal cells (Sheehan 
et al., 2007). In summary, activated -1 receptors signal 
through Gi to enhance heart rate and promote Ca
2+ 
fluxes and cross-bridge turnover kinetics, but reduce thin 
filament Ca
2+ responsiveness. Activation of receptor sig-
naling through Gi in a cascade involving Pak1 does the 
opposite, except for PLN phosphorylation. Current stud-
ies are aimed at identifying the Gi-coupled receptors that 
signal though Pak1/PP2a.
Our laboratories have reported evidence that Gi- 
coupled signaling through bradykinin (Ke et al., 2010) 
and sphingolipid receptors (Egom et al., 2010a) is able 
to activate Pak1 and PP2A in cardiac myocytes. Both of 
these receptors had been demonstrated to activate Pak1 
in other cell types. We think these pathways are signifi-
cant not only in physiological control of cardiac output, 
but also as important mechanisms in cardio protection in 
ischemia/reperfusion injury (Egom et al., 2010b). Treat-
ment of cardiac myocytes with bradykinin induced an   
increased auto-phosphorylation at Pak1 at Thr 423, and, 
as we had seen with the viral-driven expression of active 
Pak1, there was redistribution of Pak1 to the cytoplasm 
from sites localized at or near Z disk locations. In this   
receptor-stimulated pathway, there was a reduced phos-
phorylation of both PLN and cTnI, and, as expected, 
there was a reduced response to isoproterenol in myo-
cytes treated with bradykinin. In our studies related to 
sphingolipid signaling and activation of Pak, we tested 
the effects of sphingosine-1-phosphate, which is well rec-
ognized as a critical lipid operating through a family of 
G protein–coupled receptors with downstream signaling to 
diverse cellular processes. We have also tested the effects 
of a sphingosine-1-phosphate analogue, FTY 720 (fingo-
limod, 2-amino-2-[-2-(4-octyphenyl)ethyl]propane-1,3-diol-
hydrochloride), derived from a fungus, Iscaria sinclarii, 
well known in Chinese herbal medicine. FTY 720 is 
undergoing current clinical trials for the treatment of 
primary progressive multiple sclerosis. Our studies dem-
onstrated that FTY720 is able to prevent arrhythmias   
induced by simulated ischemia and reperfusion in asso-
ciation with the activation of Pak1. There was also activa-
tion of Akt. Based on our studies with active Pak1, our 
hypothesis is that the activation of the Pak1 signaling may 
be anti-arrhythmic by suppression of Ca
2+ release from 
the sarcoplasmic reticulum and the myofilaments in   
ischemia reperfusion injury.
Future prospects
Current understanding of the relative role and control 
of the kinetics of sarcomeric processes in the dynamics 
However, in a yin and yang–like manner, there is depres-
sion of sarcomere responsiveness to Ca
2+, owing largely   
to the phosphorylation of the unique N-terminal serines 
of TnI (Kobayashi and Solaro, 2005). The concept of yin 
and yang described as “how…seemingly contrary forces 
are interconnected and interdependent in the natural 
world, and how they give rise to each other in turn” is es-
pecially appropriate to describe alterations in thin fila-
ment  mechanisms  in  -adrenergic  control  of  cardiac 
dynamics, There is strong evidence from many lines of 
investigation, nicely summarized in an editorial by Ramirez- 
Correa and Murphy (2007), that especially when the 
studies  are  performed  at  physiological  temperatures, 
phosphorylation of TnI accounts is a major mechanism 
in the lusitrophic effect of -adrenergic stimulation. With 
-adrenergic stimulation, there is also evidence that cross- 
bridge turnover kinetics are enhanced. At the thick fila-
ment level there is phosphorylation of both MLC2 and 
MyBP-C, which stimulates cross-bridge turnover rate. 
Phosphorylation of cTnI has also been demonstrated to 
increase cross-bridge kinetics, but as mentioned, the ef-
fect is controversial (Tong et al., 2008). The movement of 
the cross-bridges away from the thick filament is con-
trolled by phosphorylation of both MLC2 and MyBP-C 
(Colson et al., 2010) and is the most likely mechanism 
whereby these proteins control entry of cross-bridges into 
the force-generating state.
Novel control of sarcomeric and cardiac function  
by signaling to PP2A
One of the major unresolved questions in this yin and 
yang control process is phosphatase-regulated control of 
the processes at the level of the myofilaments. Studies in 
our laboratories support the hypothesis that a major con-
trol mechanism involves signaling to PP2A by p21-acti-
vated kinase (Pak) (for review see Sheehan et al., 2007). 
Pak is a multifunctional kinase activated by Cdc42 and 
Rac1 in a Gi-coupled receptor signaling pathway. We   
reported that Pak coimmunoprecipitated with PP2A   
in both ventricular and sino-atrial nodal cells. When ex-
pressed as a constitutively active enzyme in ventricular 
myocytes, Pak1 induced a faster time to peak shortening, 
but a significantly slower rate of [Ca
2+]i decay and time of 
re-lengthening compared with controls expressing LacZ 
(Sheehan et al., 2009). The active Pak1 also induced an 
anti-adrenergic effect in blunting the response to isopro-
terenol. Moreover, spontaneous sarcoplasmic reticulum 
Ca
2+ release sparks were significantly smaller in ampli-
tude  in  active  Pak1  than  LacZ-expressing  myocytes.   
These results fit with our findings of a Pak1-induced   
dephosphorylation of TnI and L-type Ca
2+ channels.   
Surprisingly, there was no change in phospholamban 
phosphorylation at either Ser 16 or Ser 17 (Sheehan et al., 
2009). These data indicated that the yin and yang of   
adrenergic stimulation involves an active control mecha-
nism in which Ca
2+ release unit activity is suppressed and 18 Integration of sarcomeric signaling
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